Clinical Trials
Braintumor Website

There are 16 trials:
Facility: Dartmouth Hitchcock Medical Center
NCT Trial Name# of Centers

NCT00892177

  Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
308

NCT02152982

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
273

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT01781468

  Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
240

NCT01480479

  Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
206

NCT00919750

  Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
160

NCT01096368

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
150

NCT00736749

  Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
141

NCT01217437

  Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
138

NCT00437060

  Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
106

NCT02360215

  Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
100

NCT02635009

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
91

NCT02511405

  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
53

NCT02576431

  Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
36

NCT01399372

  Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
34

NCT02691923

  Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites